Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
04 Gennaio 2024 - 2:00PM
Business Wire
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced that its President and Chief Executive Officer, Steve
Mahoney, will present an overview of the company along with its
upcoming corporate priorities at the 42nd Annual J.P. Morgan
Healthcare Conference on Thursday, January 11, 2024 at 7:30am PT /
10:30am ET in San Francisco, California. In addition, the company
will webcast the question-and-answer breakout session immediately
following its presentation at 7:50am PT / 10:50am ET.
The live webcast of the presentation and breakout session can be
accessed under “Events and Presentations” on the Investors section
of the Viridian website at viridiantherapeutics.com. A replay of
the webcast will be available on the company’s website following
the event.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and engineering enables it to develop differentiated
therapeutic candidates for previously validated drug targets in
commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The company
is conducting two global Phase 3 clinical trials (THRIVE and
THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in
patients with active and chronic TED. Viridian’s goal is to advance
VRDN-001 as a best-in-class IV therapy followed by VRDN-003 as a
first- and best-in-class subcutaneous therapy for the treatment of
TED. In addition to its TED portfolio, Viridian is advancing a
novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006
and VRDN-008, which has the potential to be developed in multiple
autoimmune diseases. Viridian is also developing additional
preclinical assets in autoimmune and rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and X.
Source: Viridian Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240104648163/en/
Louisa Stone, 617-272-4604 Manager, Investor Relations
IR@viridiantherapeutics.com
Grafico Azioni Viridian Therapeutics (NASDAQ:VRDN)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Viridian Therapeutics (NASDAQ:VRDN)
Storico
Da Ott 2023 a Ott 2024